• Alias: CP-751871
    • A human mAb directed against the IGF-1R
    • Selectively binds to IGF-1R to prevent IGF1 from binding to the receptor and subsequent receptor autophosphorylation
    • Currently no active clinical trials in the United States
    • Failed to meet the end point of phase 3 trial
    • Recommended phase 2 dose: 20 mg/kg IV (day 1 of 21-day cycle)
    • Half-life: â™3 weeks
    • Common side effects: Hyperglycemia, nausea/vomiting, muscle cramps, fatigue, anorexia, increased GGT
    (Langer et al., 2014)
    Other topics in Targeted and Immunotherapy Agents